553 related articles for article (PubMed ID: 15947584)
1. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.
Sylvester RJ; van der Meijden AP; Witjes JA; Kurth K
J Urol; 2005 Jul; 174(1):86-91; discussion 91-2. PubMed ID: 15947584
[TBL] [Abstract][Full Text] [Related]
2. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
[TBL] [Abstract][Full Text] [Related]
3. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
Böhle A; Bock PR
Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
[TBL] [Abstract][Full Text] [Related]
4. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials.
Han RF; Pan JG
Urology; 2006 Jun; 67(6):1216-23. PubMed ID: 16765182
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
6. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
7. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
8. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
Witjes JA; Caris CT; Mungan NA; Debruyne FM; Witjes WP
J Urol; 1998 Nov; 160(5):1668-71; discussion 1671-2. PubMed ID: 9783928
[TBL] [Abstract][Full Text] [Related]
9. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation.
Ovesen H; Horn T; Steven K
J Urol; 1997 May; 157(5):1655-9. PubMed ID: 9112499
[TBL] [Abstract][Full Text] [Related]
11. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance.
Griffiths TR; Charlton M; Neal DE; Powell PH
J Urol; 2002 Jun; 167(6):2408-12. PubMed ID: 11992047
[TBL] [Abstract][Full Text] [Related]
12. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation.
Huncharek M; Kupelnick B
Am J Clin Oncol; 2003 Aug; 26(4):402-7. PubMed ID: 12902895
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
[TBL] [Abstract][Full Text] [Related]
14. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC; Steinberg GD
J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
[TBL] [Abstract][Full Text] [Related]
15. Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomized Phase 2 Trial (30993). Eur Urol 2011;59:438-46.
Ooi WL; Stockler M; Hayne D
Eur Urol; 2011 Jul; 60(1):e1; author reply e2-3. PubMed ID: 21489685
[No Abstract] [Full Text] [Related]
16. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results.
Losa A; Hurle R; Lembo A
J Urol; 2000 Jan; 163(1):68-71; discussion 71-2. PubMed ID: 10604316
[TBL] [Abstract][Full Text] [Related]
17. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up.
Järvinen R; Kaasinen E; Rintala E; Group TF
Scand J Urol Nephrol; 2012 Dec; 46(6):411-7. PubMed ID: 22746387
[TBL] [Abstract][Full Text] [Related]
19. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
20. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].
Nishino Y; Yasuda M; Yokoi S; Ehara H; Yamamoto N; Takahashi Y; Ishihara S; Deguchi T; Kawada Y; Takeda A; Sakai S; Takeuchi T; Taniguchi M; Minoshima K; Hamamoto Y; Kanimoto Y; Nakano M; Fujihiro S; Nezasa S; Matsuda T; Nagatani Y; Maeda S; Tamaki M; Saito A; Komeda H
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1869-73. PubMed ID: 10560414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
